Brad Shumel
Regeneron (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Food Allergy and Anaphylaxis Research, Urticaria and Related Conditions
Most-Cited Works
- → Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial(2017)1,211 cited
- → Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease(2017)850 cited
- → Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t(2017)469 cited
- → Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis(2022)422 cited
- → Conjunctivitis in dupilumab clinical trials(2019)411 cited
- → Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial(2020)370 cited
- → Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases(2021)177 cited
- → Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder(2013)149 cited
- → Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)(2019)137 cited
- → Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis(2018)136 cited